Sab Biotherapeutics Stock Price Prediction

SABS Stock  USD 3.07  0.01  0.33%   
At this time, The RSI of SAB Biotherapeutics' share price is at 56. This usually implies that the stock is in nutural position, most likellhy at or near its resistance level. The main idea of RSI analysis is to track how fast people are buying or selling SAB Biotherapeutics, making its price go up or down.

Oversold Vs Overbought

56

 
Oversold
 
Overbought
The successful prediction of SAB Biotherapeutics' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of SAB Biotherapeutics and does not consider all of the tangible or intangible factors available from SAB Biotherapeutics' fundamental data. We analyze noise-free headlines and recent hype associated with SAB Biotherapeutics, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting SAB Biotherapeutics' stock price prediction:
Quarterly Earnings Growth
(0.60)
EPS Estimate Next Quarter
(1.15)
EPS Estimate Current Year
(3.64)
EPS Estimate Next Year
(5.01)
Wall Street Target Price
12.4
Using SAB Biotherapeutics hype-based prediction, you can estimate the value of SAB Biotherapeutics from the perspective of SAB Biotherapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in SAB Biotherapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying SAB because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

SAB Biotherapeutics after-hype prediction price

    
  USD 3.07  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out SAB Biotherapeutics Basic Forecasting Models to cross-verify your projections.
For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.
Intrinsic
Valuation
LowRealHigh
0.132.6610.79
Details
Naive
Forecast
LowNextHigh
0.052.5510.68
Details
5 Analysts
Consensus
LowTargetHigh
2.092.302.55
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.91-0.91-0.91
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as SAB Biotherapeutics. Your research has to be compared to or analyzed against SAB Biotherapeutics' peers to derive any actionable benefits. When done correctly, SAB Biotherapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in SAB Biotherapeutics.

SAB Biotherapeutics After-Hype Price Prediction Density Analysis

As far as predicting the price of SAB Biotherapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in SAB Biotherapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of SAB Biotherapeutics, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

SAB Biotherapeutics Estimiated After-Hype Price Volatility

In the context of predicting SAB Biotherapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on SAB Biotherapeutics' historical news coverage. SAB Biotherapeutics' after-hype downside and upside margins for the prediction period are 0.15 and 11.20, respectively. We have considered SAB Biotherapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
3.07
3.07
After-hype Price
11.20
Upside
SAB Biotherapeutics is dangerous at this time. Analysis and calculation of next after-hype price of SAB Biotherapeutics is based on 3 months time horizon.

SAB Biotherapeutics Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as SAB Biotherapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading SAB Biotherapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with SAB Biotherapeutics, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.45 
8.13
  0.18 
 0.00  
8 Events / Month
6 Events / Month
In about 8 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
3.07
3.07
0.00 
2,085  
Notes

SAB Biotherapeutics Hype Timeline

SAB Biotherapeutics is at this time traded for 3.07. The entity has historical hype elasticity of -0.18, and average elasticity to hype of competition of 0.0. SAB is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is at this time at 0.45%. %. The volatility of related hype on SAB Biotherapeutics is about 122184.97%, with the expected price after the next announcement by competition of 3.07. About 19.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.77. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. SAB Biotherapeutics recorded a loss per share of 6.3. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 5th of January 2024. Given the investment horizon of 90 days the next forecasted press release will be in about 8 days.
Check out SAB Biotherapeutics Basic Forecasting Models to cross-verify your projections.
For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.

SAB Biotherapeutics Related Hype Analysis

Having access to credible news sources related to SAB Biotherapeutics' direct competition is more important than ever and may enhance your ability to predict SAB Biotherapeutics' future price movements. Getting to know how SAB Biotherapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how SAB Biotherapeutics may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
CMRAComera Life Sciences 0.00 0 per month 0.00 (0.01) 13.95 (12.70) 30.28 
PCSAProcessa Pharmaceuticals 0.03 5 per month 0.00 (0.25) 6.06 (5.34) 20.99 
FRTXFresh Tracks Therapeutics 0.00 0 per month 5.64  0.06  7.84 (11.11) 49.60 
THRDThird Harmonic Bio 1.22 6 per month 4.86 (0.02) 8.35 (6.74) 25.76 
CINGWCingulate Warrants 0.01 1 per month 0.00 (0.03) 34.83 (25.20) 92.13 
ANEBAnebulo Pharmaceuticals 0.00 0 per month 0.00 (0.02) 8.61 (11.48) 76.00 
CVKDCadrenal Therapeutics, Common 1.25 10 per month 6.10  0.15  17.85 (7.47) 47.47 
MNPRMonopar Therapeutics(2.62)9 per month 7.94  0.13  15.93 (9.50) 653.56 
UNCYUnicycive Therapeutics 0.01 10 per month 4.24  0.1  9.76 (7.41) 29.22 
QNRXQuoin Pharmaceuticals Ltd(0.02)9 per month 6.74  0.05  17.65 (9.68) 74.46 
CDIOCardio Diagnostics Holdings 0.01 5 per month 0.00 (0.06) 12.00 (13.16) 57.04 
VRAXVirax Biolabs Group 0.02 4 per month 0.00 (0.16) 9.65 (13.45) 61.28 
PXMDPaxMedica, Common Stock 0.00 0 per month 0.00 (0.23) 7.63 (7.28) 23.71 

SAB Biotherapeutics Additional Predictive Modules

Most predictive techniques to examine SAB price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for SAB using various technical indicators. When you analyze SAB charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About SAB Biotherapeutics Predictive Indicators

The successful prediction of SAB Biotherapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as SAB Biotherapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of SAB Biotherapeutics based on analysis of SAB Biotherapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to SAB Biotherapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to SAB Biotherapeutics's related companies.
 2021 2022 2023 2024 (projected)
Graham Number44.9926.2942.2426.62
Receivables Turnover7.64.33.873.16

Story Coverage note for SAB Biotherapeutics

The number of cover stories for SAB Biotherapeutics depends on current market conditions and SAB Biotherapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that SAB Biotherapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about SAB Biotherapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

SAB Biotherapeutics Short Properties

SAB Biotherapeutics' future price predictability will typically decrease when SAB Biotherapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of SAB Biotherapeutics often depends not only on the future outlook of the potential SAB Biotherapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. SAB Biotherapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding5.5 M
Cash And Short Term Investments56.6 M

Additional Tools for SAB Stock Analysis

When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.